Key result
FK506 immunosuppression enabled the survival of transplanted myoblasts expressing beta-galactosidase for up to 12 weeks in monkeys, compared to no survival at 4 weeks without immunosuppression.
Why the study?
Does FK506 immunosuppression improve the survival of transplanted myoblasts and reduce immune response in monkeys?
Does FK506 immunosuppression improve the survival of transplanted myoblasts and reduce immune response in monkeys?
FK506 effectively controls short-term immune reactions following myoblast transplantation in monkeys, suggesting potential utility for Duchenne Muscular Dystrophy patients.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; hypothesis-generating for FK506-assisted myoblast transplantation in primates.
Myoblasts were grown from monkey muscle biopsies and infected in vitro with a defective retroviral vector containing a cytoplasmic beta-galactosidase (beta-gal) gene. These myoblasts were then transplanted to 14 different monkeys, 6 of which were immunosuppressed with FK506. Without immunosuppression, only a few myoblasts and myotubes expressing beta-gal were observed 1 week after the transplantation, but no cells expressing beta-gal were observed after 4 weeks. This result was attributed to immune responses since infiltration by CD4+ or CD8+ lymphocytes was abundant 1 week after transplantation but not after 4 weeks. The expression of interleukin 6 (IL-6), interleukin 2 (IL-2), granulocyte/macrophage colony stimulating factor (GM-CSF), transforming growth factor-beta (TGF-beta) and granzyme B mRNAs was increased in the myoblast-injected muscle indicating that the infiltrating lymphocytes were activated. Moreover, antibodies against the donor myoblasts were detected in 3 out of 6 cases. When the monkeys were immunosuppressed with FK506, muscle fibers expressing beta-galactosidase (beta-gal) were present 1, 4 and 12 weeks after the transplantation. There was neither significant infiltration by CD4 or CD8 lymphocytes, nor antibodies detected. The mRNA expression of most cytokines was significantly reduced as compared to the nonimmunosuppressed monkeys. These results indicate that FK506 is effective in controlling short-term immune reactions following myoblast transplantation in monkeys and suggest that it may prove useful for myoblast transplantation in Duchenne Muscular Dystrophy patients.
No takes yet. Share an insight, caveat, or question.
Kinoshita et al. (1996) studied Myoblast transplantation (n=14). FK506 vs. No immunosuppression was evaluated on Presence of muscle fibers expressing beta-galactosidase. FK506 immunosuppression enabled the survival of transplanted myoblasts expressing beta-galactosidase for up to 12 weeks in monkeys, compared to no survival at 4 weeks without immunosuppression.
Synapse has enriched 10 related papers. Consider them for comparative context: